Cardiovascular safety of proton pump inhibitors in post-percutaneous coronary intervention patients receiving dual antiplatelet therapy: A meta-analysis

Table 1 Study design of included studies

Ref.	Year	Country	Type of study	Total patients (n)	Study group (n)	Control group (n)	PPI used	Duration of study
Wei et al[9]	2016	China	RCT	207	123	84	Pantoprazole 40 mg	6 months
Vaduganathan et al[10]	2016	Spain and United States	RCT	2676	870	1806	Omeprazole 20 mg	110 days
Ren et al[11]	2011	Chinese	RCT	172	86	86	Omeprazole	30 days
Jensen et al[12]	2017	Denmark	RCT	2009	870	1806	Pantoprazole	1 year
Kim et al[13]	2024	Korea	Retrospective	2266	1133	1133	Non-selective PPI	15 years
Rossini et al[14]	2011	Italy	Retrospective	1328	1158	170	Non-selective PPI	12 months
Yasu et al[15]	2010	Japan	Retrospective	302	103	199	Rabeprazole	395 days
Aihara et al[16]	2012	Japan	Retrospective	1000	500	500	Non-selective PPI	1 year
Chandrasekhar et al[17]	2017	United States and Europe	Retrospective	4635	1062	3573	Non-selective PPI	24 months

RCT: Randomized controlled trial; PPI: Proton pump inhibitor.